Sanofi ditches Danish insulin deal
The French drug group Sanofi has walked away from a development deal with Denmark’s Ascendis Pharma, the biotech firm said last week in an SEC filing.
BY STEFAN SINGH KAILAY
The company, which is listed on the Nasdaq in New York, saw its share price decline 3.5% in the aftermarket following the announcement. The share price had gone up by 7.2% that day prior to the news.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Ascendis bags USD 111.5 million in IPO
For abonnenter
Ascendis sets IPO target
For abonnenter
Ascendis Pharma launches US IPO
For abonnenter
